{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:13:39Z","timestamp":1788300819379,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.129000","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:15:50Z","timestamp":1785827750000},"page":"129000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Entering into life-course immunization: Process, significance, and prospects of HPV vaccine inclusion into the national immunization program of China"],"prefix":"10.1016","volume":"89","author":[{"given":"Yin","family":"Zundong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Xiaoxue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Rodewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Fuzhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Hongbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.vaccine.2026.129000_bb0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.46234\/ccdcw2024.080","article-title":"Estimated human papillomavirus vaccine coverage among females 9-45 years of age - China, 2017-2022","volume":"6","author":"Chen","year":"2024","journal-title":"China CDC Wkly"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129000_bb0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.vaccine.2026.129000_bb0015","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. Available from: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/4e245e89-ddcc-488f-97c7-9de5e08524ef\/content; [accessed 23 Feb 2026]."},{"issue":"9","key":"10.1016\/j.vaccine.2026.129000_bb0020","first-page":"1705","article-title":"Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18","volume":"20","author":"Chen","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129000_bb0025","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129000_bb0030","first-page":"345","article-title":"Economic burden of human papilloma virus related diseases in China: a systematic review and synthetic analysis","volume":"27","author":"He","year":"2023","journal-title":"Chin J Dis Control Prev"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129000_bb0035","doi-asserted-by":"crossref","first-page":"675","DOI":"10.21147\/j.issn.1000-9604.2023.06.11","article-title":"Estimation of economic burden throughout course of cervical squamous intraepithelial lesion and cervical cancer in China: a nationwide multicenter cross-sectional study","volume":"35","author":"Chen","year":"2023","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.vaccine.2026.129000_bb0040","unstructured":"The People\u2019s Republic of China. Action plan for accelerating cervical cancer elimination (2023\u20132030). 2023. Available from: https:\/\/www.gov.cn\/zhengce\/zhengceku\/2023-01\/21\/content_5738364.htm; [accessed 23 Feb 2026]."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129000_bb0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12916-021-01930-9","article-title":"Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study","volume":"19","author":"Xia","year":"2021","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129000_bb0050","first-page":"425","article-title":"Health economics evaluation of vaccination strategies for different human papillomavirus vaccines for 12-year-old female adolescents in China","volume":"59","author":"Li","year":"2025","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi."},{"issue":"50","key":"10.1016\/j.vaccine.2026.129000_bb0055","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.46234\/ccdcw2025.262","article-title":"Technical and implementation guidelines for the introduction of human papillomavirus vaccine into China\u2019s national immunization program","volume":"7","author":"Wang","year":"2025","journal-title":"China CDC Wkly"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129000_bb0060","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.vaccine.2024.02.077","article-title":"Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: interim analysis from a phase 3 clinical trial","volume":"42","author":"Zaman","year":"2024","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129000_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0302379","article-title":"Prevalence of caregiver hesitancy for vaccinations in children and its associated factors: a systematic review and meta-analysis","volume":"19","author":"Maamor","year":"2024","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.129000_ce.other-ref_idq_gyx_ckc","unstructured":"Standing Committee of the National People's Congress. Vaccine Administration Law of the People's Republic of China [EB\/OL]. Available from: \u200b\u200b\u200bhttps:\/\/en.moj.gov.cn\/2021-06\/26\/c_636456.htm; [accessed 15 July 2026]."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129000_bb0075","doi-asserted-by":"crossref","first-page":"2444008","DOI":"10.1080\/21645515.2024.2444008","article-title":"Socioeconomic disparities in childhood vaccine hesitancy among parents in China: the mediating role of social support and health literacy","volume":"21","author":"Yao","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.129000_bb0080","first-page":"1303","article-title":"Analysis of the current status and influencing factors of vaccine hesitancy among guardians of children in China\u2019s national immunization program","volume":"12","author":"Song","year":"2023","journal-title":"Chin J Prev Med"},{"key":"10.1016\/j.vaccine.2026.129000_bb0085","unstructured":"The People\u2019s Republic of China Government work report. 2025. Available from: https:\/\/www.gov.cn\/gongbao\/2025\/issue_11946\/202503\/content_7015861.html; [accessed 10 March 2026]."},{"key":"10.1016\/j.vaccine.2026.129000_bb0090","unstructured":"NDCPA. Notice on the inclusion of human papillomavirus (HPV) vaccines into the national immunization Program. 2025. Available from: https:\/\/www.gov.cn\/zhengce\/zhengceku\/202510\/content_7046467.htm; [accessed 10 July 2026]."},{"key":"10.1016\/j.vaccine.2026.129000_bb0095","unstructured":"Center for Drug Evaluation, NMPA. Drug clinical trial registration and information disclosure platform. 2025. Available from: http:\/\/www.chinadrugtrials.org.cn\/index.html; [accessed 2 March 2026]."},{"key":"10.1016\/j.vaccine.2026.129000_bb0100","unstructured":"Center for Drug Evaluation, NMPA. Technical guidelines on clinical trials for human papillomavirus (HPV) vaccines (Trial). 2023. Available from: https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/f1623a35ec967425dd37b2bb8bcac3b5; [accessed 13 March 2026]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:21:32Z","timestamp":1788297692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26008091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"alternative-id":["S0264410X26008091"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129000","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Entering into life-course immunization: Process, significance, and prospects of HPV vaccine inclusion into the national immunization program of China","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129000"}}